Makers of Praluent Win New Trial in Patent Dispute With Amgen
A federal appeals court set aside a lower-court verdict against Sanofi and Regeneron Pharmaceuticals in their dispute with Amgen involving patents on Amgen’s cholesterol drug Repatha and lifted an injunction against the marketing of their rival drug Praluent.
The U.S. Court of Appeals for the Federal Circuit ordered a new trial in the case.
The case originated in 2014 when Amgen sued Sanofi and Regeneron, claiming that Praluent (alirocumab) infringed on patents for Repatha (evolocumab). Both medicines are injectable antibodies that reduce LDL cholesterol by targeting PCSK9 proteins.